SCL-1

SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and natural killer cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer[1][2].

Product Specifications

CAS Number

[1061105-16-5]

UNSPSC

12352100

Target

PD-1/PD-L1

Related Pathways

Immunology/Inflammation

Field of Research

Cancer

Smiles

CC1CCCCN1C(C2CCN(CC2)C3=NN4C(C=C3)=NN=C4C(F)(F)F)=O

Molecular Formula

C18H23F3N6O

Molecular Weight

396.41

References & Citations

[1]Ikeya T, et al. Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model. Sci Rep. 2025 Jul 24;15 (1) :26918.|[2]Akiyama Y, et al. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer Res. 2022 Nov;42 (11) :5233-5247.